financetom
JNJ
financetom
/
Healthcare
/
JNJ
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Johnson & JohnsonJNJ
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.

It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension.

This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use.

Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand.

This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Latest News >
Can The Big $5 Billion Crypto Options Expiry Event Today Shift Market Momentum? 
Can The Big $5 Billion Crypto Options Expiry Event Today Shift Market Momentum? 
Aug 30, 2024
Around 62,000 Bitcoin options contracts are due for expiry on Friday, August 30. They have a notional value of around $3.65 billion. Today’s options expiry event is a large one due to it being the end of the month. However, spot markets are rarely rattled by these derivatives developments which serve more as an indication of market sentiment. Bitcoin Options...
UTime Signs Agreement to Acquire Bowen Therapeutics' Laboratory; Shares Drop
UTime Signs Agreement to Acquire Bowen Therapeutics' Laboratory; Shares Drop
Aug 30, 2024
12:31 PM EDT, 08/28/2024 (MT Newswires) -- UTime ( WTO ) said Wednesday it has entered into a non-disclosure agreement with Bowen Therapeutics for the purchase of its laboratory at UMASS Medical School. Bowen Therapeutics has made progress in monkeypox vaccine research, including the development of a hexavalent recombinant protein vaccine using recombinant technology, the company said. Financial details were...
Norwegian Cruise Line Unit to Add New Winter Sailings in Early 2026
Norwegian Cruise Line Unit to Add New Winter Sailings in Early 2026
Aug 30, 2024
12:38 PM EDT, 08/28/2024 (MT Newswires) -- Norwegian Cruise Line Holdings' ( NCLH ) Oceania Cruises unit said Wednesday it will have new Caribbean and Panama Canal winter sailings, starting in early 2026, with departures from Tampa, Florida. Oceania Cruises said that in March 2026, its 670-guest Insignia will become the first ultra-premium cruise line to sail from Port Tampa...
Soccer-Hard-working Chiesa unlikely to feature against Man United, says Liverpool's Slot
Soccer-Hard-working Chiesa unlikely to feature against Man United, says Liverpool's Slot
Aug 30, 2024
Aug 30 (Reuters) - Liverpool manager Arne Slot said he was excited about the arrival of versatile attacker Federico Chiesa but would be careful to introduce the 26-year-old into action gradually. Chiesa, who joined from Juventus on Thursday in a deal worth 12 million euros ($13.30 million) plus three million in add-ons, was unlikely to feature when Liverpool visit Manchester...
Copyright 2023-2025 - www.financetom.com All Rights Reserved